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Edited by Lukas HuberAbstract Treatment of transformed cells from leukemia or so-
lid tumors with histone deacetylase inhibitors (HDACi) was
shown to increase their sensitivity to NK cell lysis. In this study,
treatment of IL-2-activated NK cells with HDACi including
suberoylanilide hydroxamic acid and valproic acid was studied.
Both drugs at therapeutic concentrations inhibited NK cell cyto-
toxicity on human leukemic cells. This inhibition was associated
with decreased expression and function of NK cell activating
receptors NKp46 and NKp30 as well as impaired granule exocy-
tosis. NFjB activation in IL-2-activated NK cells was inhibited
by both HDACi. Pharmacologic inhibition of NFjB activity re-
sulted in similar eﬀects on NK cell activity like those observed
for HDACi. These results demonstrate for the ﬁrst time that
HDACi prevent NK cytotoxicity by downregulation of NK cell
activating receptors probably through the inhibition of NFjB
activation.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The use of histone deacetylase inhibitors (HDACi) as anti-
cancer agents has received great attention in recent times.
Major classes of HDACi include short chain fatty acids [e.g.,
phenylbutyrate, valproic acid (VPA)], derivatives of hydroxa-
mic acid [e.g., PXD101, suberoylanilide hydroxamic acid
(SAHA), trichostatin A], the benzamide derivative MS-275,
and the naturally occurring depsipeptide FR901228 [1]. Clinical
studies have shown that pharmacologic relevant levels of HDA-
Ci like SAHA and VPA can be achieved safely in humans and
that treatment of cancer is possible [1]. Antitumoral activity wasAbbreviations: CT, threshold cycles; DNAM-1, DNAX accessory
molecule-1; FCS, fetal calf serum; HDACi, histone deacetylase inhi-
bitors; IL-2, interleukin-2; IMDM, Iscove’s modiﬁed Dulbecco’s me-
dium; KIR, killer immunoglobulin-like receptors; LFA-1, lymphocyte
function antigen-1; mAb, monoclonal antibody; MICA/B, MHC class
I-related chain A/B; NCR, natural cytotoxic receptors; NFjB, Nuclear
factor kappa B; NK, natural killer; NKG2A, NK group 2, member A;
NKG2D, NK group 2, member D; PE, phycoerythrin; RFU, relative
ﬂuorescent units; SAHA, suberoylanilide hydroxamic acid; VPA, val-
proic acid
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doi:10.1016/j.febslet.2007.02.045ascribed to the direct eﬀects of HDACi on tumor cells in induc-
tion of growth arrest with apoptosis or diﬀerentiation. More-
over, HDACi may inﬂuence tumor growth by angiogenesis
inhibition [2,3] and increasing tumor cell immunogenicity [4].
Natural killer (NK) cells as components of the innate
immunity substantially contribute to the elimination of virus-
infected cells as well as antitumor immune response [5].
Although NK cells can kill target cells spontaneously without
prior stimulation, a delicate balance between inhibitory [killer
immunoglobulin-like receptors (KIR), CD94-NK group 2,
member A (NKG2A)] and activating signals [natural cytotoxic
receptors (NCRs-NKp30, NKp44 and NKp46), NK group 2,
member D (NKG2D) and DNAX accessory molecule-1
(DNAM-1)] tightly regulates their activation [5].
The modulation of immune responses which may be impor-
tant for NK cell activity through epigenetic mechanisms such
as acetylation and deacetylation has been studied by some
groups. Some of these studies were based on the eﬀects of HDA-
Ci on the expressions of costimulatory/adhesion molecules [e.g.,
CD86 and intracellular adhesion molecule-1 (ICAM-1)] and
ligands for the activating receptors of NK cells [e.g., MHC class
I-related chain A and B (MICA/B), UL16 binding proteins] in
leukemic and tumor cell lines, respectively [6–8].
Increased NK cell-mediated lysis after VPA treatment was
initially reported for neuroblastoma cells. Treatment of neuro-
blastoma cells with 0.5 mM VPA increased their sensitivity to
lymphokine-activated killer lysis [4]. These results were later
conﬁrmed in hepatoma cells. Here the authors showed that
VPA increased transcription of MICA and MICB in hepato-
cellular carcinoma cells, leading to increased cell surface, solu-
ble and total MIC protein expression as well as increased lysis
by NK cells [8]. SAHA treatment was also reported to increase
functional expression of NKG2D ligands including MICA/B
in Jurkat T cell leukemia thereby making them more sensitive
to NK cell-mediated lysis [7]. On the other hand, direct eﬀect
of HDACi on NK cell activity was not studied. In the present
study we tested lytic activity of human polyclonal NK cells
treated with two HDACi, SAHA and VPA, on several leuke-
mic cell lines.2. Materials and methods
2.1. Cell culture
Human erythroleukemic K562 cells, Jurkat T cell leukemia and leu-
kemic promyelocytic HL-60 cell lines were obtained from ATCC
(Manassas, VA). P815 FccR+ murine cell line was from DSMZ,
Braunschweig, Germany. K562 cell line was grown in Iscove’s
Modiﬁed Dulbecco’s Medium (IMDM) with 20% fetal calf serumblished by Elsevier B.V. All rights reserved.
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with 10% FCS. Media and supplements were from Seromed (Berlin,
Germany).
2.2. Reagents and monoclonal antibodies
VPA was obtained as the sodium salt from Sigma (Deisenhofen,
Germany), SAHA was from Alexis Biochemicals (Gruenberg, Ger-
many), recombinant human interleukin-2 (IL-2) from Cell Concepts
(Umkirch, Germany), BAY11-7085 was obtained from Calbiochem
(Darmstadt, Germany). The following phycoerythrin (PE)-conjugated
anti-human monoclonal antibodies (mAbs) were used: NKp30,
NKp44, NKp46, NKG2A all from Beckman Coulter (Marseille,
France) and KIR/CD158, CD132, CD122, CD25 from R&D Systems
(Wiesbaden, Germany). Unconjugated mouse monoclonal DNAM-1
and NKG2D and ﬂuorescein isothiocynate conjugated LFA-1, PE-
conjugated Perforin were from BD Pharmingen (San Diego, CA).
PE-conjugated granzyme B was from Abcam (Cambridge, UK). For
redirected killing experiments, puriﬁed NKp30 and NKp46 mAb
(Beckman Coulter) were used.2.3. Cytotoxicity assay and ﬂow cytoﬂuorometric analysis
Cytotoxicity of NK cells was determined by the recently established
4h coupled luminescent method using the ‘‘aCella-Tox’’ kit (Cell Tech-
nology, Mountain View, CA), as described [9]. K562, P815 FccR+,
Jurkat T cell or HL-60 cell lines were used as target cells. For redi-
rected killing experiments, 1 lg/ml of the corresponding puriﬁed
mAb was used. Flow cytometry (FACS Calibur; Becton Dickinson,
Mountain View, CA) was used for cell surface expression analysis
while cellular DNA content was measured using propidium iodide
staining as described [10]. In case of unconjugated antibodies PE-con-
jugated isotype-speciﬁc goat antimouse second reagent (R&D Systems)
was used.
2.4. Polyclonal NK cell preparation
Human peripheral blood mononuclear cells were isolated from the
blood of healthy volunteers by Ficoll-Hypaque centrifugation followed
by separation using the MACS NK cell isolation kit II (Miltenyi Bio-
tec, Bergisch Gladbach, Germany) according to manufacturer’s proto-
col. Flow cytometric analysis to determine purity of NK cells showed
that more than 90% of the cells were CD56+CD3 (not shown).2.5. Real-time RT-PCR
Total RNA was extracted from IL-2-activated NK cells either un-
treated or treated with 0.5 mM VPA or 0.5 lM SAHA using TRI re-
agent (Sigma, Steinheim, Germany). Oligo(dT)-primed cDNA was
prepared by standard techniques. Relative quantiﬁcation of gene
expression after IL-2 activation and either VPA or SAHA treatment
was performed in real-time RT-PCR (reverse transcriptase-polymerase
chain reaction) using SYBR Green reagents (Applied Biosystems,
Darmstadt, Germany). To internally standardize the levels of gene
expression, we used the b-actin housekeeping gene. Ampliﬁcations
were performed with the ABI PRISM 7000 Sequence Detection System
in a 50 ll ﬁnal volume using 40 cycles of a two-step PCR (15 s at 94 C
and 60 s at 60 C) after initial denaturation (95 C for 15 min). Primers
for NKp46 are: forward 5 0-GGCAGAATCTGAGCGATGTCTT-3 0;
reverse 5 0-GCTTTTCCTTTGGAACCATGAA-3 0. Primers for
NKp30 are: forward 5 0-TGATCATGGTCCATCCAGGA-3 0; reverse
5 0-AATGGCCAGTCTCCCTTGG-3 0. Primers for b-actin are: for-
ward 5 0-CGCGAGAAGATGACCCAGAT-3 0; reverse 5 0-CAGA-
GGCGTACAGGGATAGCA-3 0. Threshold cycles (CT) were
determined as the mean of triplicate determinations of samples. Rela-
tive expression of each transcript was obtained by calculating the DCT
as the diﬀerence between the PCR CT of the analyzed gene (NKp46 or
NKp30) and b-actin used as reference. The diﬀerence in expression lev-
els between untreated and treated NK cells was calculated by compar-
ing the DCT of untreated NK cells (used as control) to that of samples
from VPA or SAHA treated NK cells.2.6. NK receptors cross-linking and perforin/granzyme B granule release
NK cells were stimulated by mAb cross-linking as previously de-
scribed [11]. Brieﬂy, after 4 days of culture in IL-2 with or without
VPA or SAHA, cells were labeled with 1 lg/ml appropriate mAbs
for 30 min at 4 C. After washing, cells were stimulated with 10 lg/ml AﬃniPure F(ab 0)2 Fragment Goat Anti-Mouse IgG (Jackson
ImmunoResearch, West Grove, PA) for 5 min at 37 C. Reaction
was stopped with ice-cold phosphate buﬀered saline. After overnight
incubation at 37 C, supernatants were collected for analysis and quan-
tiﬁcation of granule release by ELISA assay (Perforin/Granzyme B-
ELISA kit, Diaclone Research, Besancon Cedex, France) according
to manufacturer’s instructions.
2.7. Measurement of NFjB activation
Nuclear factor kappa B (NFjB) p50 and NFjB p65 activation were
determined using the TransAM NFjB Chemi kit (Active Motif,
Carlsbad, CA). Brieﬂy, puriﬁed NK cells were treated with 100 U/ml
IL-2, and either 0.5 lM SAHA, 0.5 mM VPA, or 1 lM BAY 11-
7085 were added simultaneously for 4 days. NK cells treated with
100 U/ml IL-2 only were used as control. Nuclear extracts were then
prepared using the nuclear extract kit (Active Motif). The extracts were
used for the NFjB activation assay according to the manufacturer’s
protocols. A mutated consensus oligonucleotide (should have no eﬀect
on NFjB binding) as well as a wild-type consensus oligonucleotide (a
competitor for NFjB binding) was used to monitor the speciﬁcity of
the assay. Twenty pmol/well of each oligonucleotide was used for the
assay.3. Results
3.1. Eﬀect of HDACi on viability of NK cells
We ﬁrst studied eﬀects of HDACi at clinically relevant con-
centrations [12,13] (0.25–1 mM and 0.5–2 lM for VPA and
SAHA, respectively) on viability of NK cells. For this purpose,
NK cells were cultured simultaneously for 4 days with IL-2
and SAHA or VPA. Dead cells were identiﬁed by fractional
DNA content (‘‘sub-G1 fraction’’). NK cells treated with IL-
2 alone were used as control. Results revealed SAHA to be
clearly toxic to NK cells in the range of therapeutic concentra-
tions. About 48% of NK cells were found in the sub G1 phase
(indicating induction of cell death) upon exposure to 2 lM
SAHA compared to 9% in control cells (Fig. 1). In contrast,
0.5 lM SAHA treatment resulted in no or at most minimal
NK cell death, while 60.5 mM VPA was only slightly toxic
to NK cells (1.6% cell death induction when compared to con-
trol) (Fig. 1). Similar results were obtained by trypan blue
exclusion assay (not shown). Both VPA and SAHA also
blocked cell cycle progression into the S- and G2/M Phase in
a dose dependent manner (Fig. 1). Based on these results we
selected 0.5 mM VPA and 0.5 lM SAHA to investigate the
inﬂuence of non-toxic HDACi concentrations on NK cell
activity.3.2. HDACi suppress IL-2-mediated NK cell cytotoxicity
We investigated the role of HDACi on NK cell cytotoxicity.
IL-2-activated NK cells were treated with either SAHA or
VPA for 4 days after which the cytotoxicity against K562 cells
was determined by a 4 h coupled luminescent method using the
‘‘aCella-Tox’’ kit [9]. SAHA or VPA and IL-2 were added at
indicated concentrations simultaneously to NK cell cultures.
Interestingly, both SAHA and VPA dramatically suppressed
IL-2-activated NK cell cytotoxicity in an eﬀector:target (E:T)
cell ratio-dependent manner (Fig. 2A). Decreased NK lytic
activity of HDACi treated NK cells was also observed in other
leukemic cell lines including Jurkat T cells and HL-60 cells
(Fig. 2B). A 24 h pretreatment of Jurkat T cells and HL-60
cells with SAHA resulted in almost 60% (54% vs. 86%) and
14% (57% vs. 65%) increased NK cell-mediated lysis in SAHA
treated Jurkat and HL-60 cells, respectively. The increased NK
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Fig. 1. Viabilty and proliferation of NK cells after exposure to HDACi. Primary NK cells from healthy donors were treated simultaneously with
100 U/ml IL-2 and either VPA or SAHA at indicated concentrations for 4 days. The eﬀect of HDACi on cell cycle was determined by staining cells
with propidium iodide. M1, M2, M3 and M4 indicate sub G1, G0/G1, S and G2/M phases, respectively; empty histograms represent VPA treated
cells; grey histograms represent SAHA treated cells; black histogram represents untreated (control) NK cells; numbers in parentheses indicate
respective concentrations of HDACi used; values represent percentage of cells in the diﬀerent phases. The percentages of cells in G0/G1, S and G2/M
phases were deduced from the number of viable cells (set to 100%) after subtracting the dead cells (sub G1) from total gated cells. One representative
of three diﬀerent experiments is shown.
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cells were used as eﬀector cells (Fig. 2B). Taken together, Jur-
kat T cells and HL-60 cells become more susceptible to NK
cell-mediated lysis upon exposure to SAHA while NK cell
activity gets repressed upon treatment with SAHA. In con-
trast, treatment of K562 cell line for 24 h with 1 lM SAHA
did not increase its susceptibility to NK cell lysis (data not
shown).
3.3. HDACi downmodulate NK cell activating receptors
expression and NK cell function
NK cell cytotoxicity is a complex process that requires adhe-
sion to target cells, synapse formation and signal transduction
leading to granule polarization and exocytosis. Accordingly, it
is conceivable that HDACi might interfere with diﬀerent steps
in the process. To address these issues, we investigated the sur-
face expression patterns of NKp30, NKp44, NKp46, NKG2D
and DNAM-1, NKG2A and KIR in untreated as well as in
SAHA and VPA treated NK cells. A correlation between
NK cell cytotoxicity and NK cell receptor expression pattern
was observed. The lytic capacity of NK cells treated with
HDACi was associated with a high decreased surface expres-
sion of NKp30 and NKp46 while NKp44, NKG2D and
DNAM-1 were not signiﬁcantly changed. No changes were ob-served in the surface expression of KIR and NKG2A inhibi-
tory receptors (Fig. 3A). To show whether the expressions of
NKp46 and NKp30 are also inﬂuenced at the transcriptional
level upon HDACi treatment, we examined the gene expres-
sion patterns of NKp46 and NKp30 in untreated and HDACi
treated NK cells. Real-time RT-PCR results revealed a ﬁve-
and ninefold-decrease as well as a 9- and 12-fold-decrease
expression in NKp46 and NKp30, respectively, for VPA and
SAHA treated NK cells when compared to untreated NK cells
(Fig. 3B). HDACi suppressed NK cell activity and NCR sur-
face expression only when added simultaneously with IL-2,
while they did not inﬂuence NK cells cultured without IL-2.
Basically NK cell activating/inhibitory receptor expression lev-
els were three–fourfold higher in IL-2 cultured NK cells than
in NK cells cultured without IL-2 (not shown). Since NK
cytolysis also depends on binding mediated by adhesion mole-
cules like lymphocyte function antigen-1 (LFA-1) we deter-
mined eﬀects of HDACi on LFA-1 surface expression. We
also determined whether HDACi inﬂuence IL-2 receptor since
only NK cells cultured with IL-2 showed impaired activity
upon HDACi treatment. HDACi did not modify the expres-
sion neither of LFA-1 nor of IL-2 receptors (CD25, CD122,
CD132) on NK cells (not shown). These results suggest that
HDACi act directly on selected NK cell receptors rather than
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Fig. 2. HDACi suppress NK cell cytotoxicity. Primary NK cells from
healthy donors were treated simultaneously with 100 U/ml IL-2 and
either 0.5 mM VPA or 0.5 lM SAHA for 4 days. Primary NK cells
treated only with 100 U/ml IL-2 were used as control. (A) A 4 h NK
cell cytotoxicity assay against K562 target cells was performed at
indicated E:T ratios. Columns represent means of triplicate of one
representative experiment; error bars indicate ±standard deviation
(S.D.). (B) A 4 h NK cell cytotoxicity assay against Jurkat T cells and
HL-60 cells, pretreated with 1 lM SAHA for 24 h at an E:T ratio of
2:1 was carried out. [] indicate without SAHA, [+] indicate with
SAHA. Columns represent means of triplicate of one representative
experiment; error bars indicate ±standard deviation (S.D.).
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NK cell binding to target cells.
To assess whether HDACi-induced modulation of NKp46
and NKp30 receptors resulted in an alteration of NK cell
activity, treated and untreated NK cells were compared in a
redirected killing assay against FccR+ P815 target cell line.
The FccR+ P815 cell line has been extensively used for mAb-
mediated redirected killing assays using NK cells and mAbs
capable of triggering their cytolytic functions [14–16]. This
would allow us assess in a cytolytic assay the direct eﬀect of
VPA and SAHA on the speciﬁc activity of the trigerring recep-
tors NKp46 and NKp30. As shown in Fig. 3C, treatment of
NK cells with VPA and SAHA clearly reduced the ability of
anti-NKp46 and anti-NKp30 mAbs to induce NK cell-medi-
ated lysis. These ﬁndings suggest that HDACi may aﬀect
NK cell function by interfering with the expression and the
function of NKp46 and NKp30 triggering receptors. To vali-
date the eﬀect of HDACi on NKp46 and NKp30 expression
and function, we analyzed perforin and granzyme B degranu-
lation after cross-linking of NKp46 and NKp30 with mAbs as
described [11]. As shown in Fig. 3D, an impaired perforin
release is observed upon treatment of NK cells with VPA
and SAHA. mAb cross-linking of NK cells resulted in
increased perforin release, further indicating the direct eﬀect
of HDACi on NKp46 and NKp30. Similar results were ob-tained for granzyme B degranulation (not shown). It is worthy
to mention that intracellular perforin (25.6 ± 2, 23.3 ± 4,
23.7 ± 2 relative ﬂuorescent units (RFU) for control, VPA
treated, and SAHA treated NK cells, respectively) and gran-
zyme B (48.19 ± 2, 52.2 ± 4, 50.4 ± 2 RFU for control, VPA
treated, and SAHA treated NK cells, respectively) expressions
using ﬂow cytometry were not signiﬁcantly aﬀected by HDACi
treatment.3.4. SAHA and VPA suppress NFjB activation in IL-2-
activated NK cells
It was previously reported by Zhou et al. [17] and Kim et al.
[18] that IL-2 increases NK cell cytotoxicity and proliferation
through activation of NFjB signaling pathway. To verify a
possible role of NFjB in our experiment, we compared the ef-
fect of HDACi with that of a potent NFjB inhibitor BAY 11-
7085 on NFjB binding. NK cells were cultured simultaneously
for 4 days with 100 U/ml IL-2 and either HDACi or BAY 11-
7085. NFjB activation was then measured. BAY 11-7085 as
well as SAHA and VPA inhibited NFjB activity (Fig. 4).
BAY 11-7085 (not toxic to NK cells at concentration used- try-
pan blue exclusion counts) also abrogated NK cell lysis of
K562 and suppressed surface expression of NK cell activating
receptors (not shown). These results suggest that HDACi pre-
vent IL-2-activated NK cell cytotoxicity by suppressing NK
cell activating receptors in association with the inhibition of
NFjB activation.4. Discussion
HDACi induce growth arrest and diﬀerentiation of trans-
formed cells in association with increased cellular sensitivity
to NK cell-mediated lysis. However, the results shown in this
study provide for the ﬁrst time evidence that treatment of
NK cells with HDACi can suppress their lytic activity against
leukemic cells. NK cell inhibitory eﬀects were associated with
the suppression of surface expression and function of speciﬁc
triggering receptors (NKp46 and NKp30) responsible for the
induction of NK cell-mediated cytotoxicity. This inhibitory
eﬀect was also eﬀective at the transcriptional level. Moreover,
impaired granule release was observed upon treatment of NK
cells with VPA and SAHA. After cross-linking of NK cells
with NKp46 and NKp30 granule release were increased, fur-
ther indicating the direct eﬀect of HDACi on NKp46 and
NKp30. HDACi acted directly on selected NK cell receptors
rather than by interfering with the ability of NK cells to re-
spond to IL-2. On the other hand, surface expression levels
of inhibitory receptors including KIR and NKG2A were not
inﬂuenced by HDACi treatment, indicating a speciﬁc eﬀect
of HDACi on NK cell triggering receptors.
Independent reports by Cinatl et al. [4], Skov et al. [7], and
Armeanu et al. [8] described an increased NK cell-mediated
lysis of certain tumors upon treatment with HDACi, VPA
and SAHA. Although we found in concert with these studies
[4,7,8] that treatment of leukemic cells with HDACi increases
their sensitivity to NK cell lysis, the increased sensitivity was
however reversed when NK cells were pretreated with SAHA.
These ﬁndings suggest that direct inhibitory eﬀect of HDACi
on lytic NK cells may overweigh the HDACi-induced
increased sensitivity of leukemic cells to NK cell lysis.
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Fig. 3. HDACi downmodulate expression of NK cell activating receptors. Primary NK cells from healthy donors were treated simultaneously with
100 U/ml IL-2 and either 0.5 mM VPA or 0.5 lM SAHA for 4 days. Primary NK cells treated only with 100 U/ml IL-2 were used as control. (A)
Flow cytometric analysis for the expression of indicated NK cell activating or inhibitory receptors. Columns indicate relative expression of one
representative of at least ﬁve separate experiments. (B) Real-time RT-PCR for the mRNA expression levels of the diﬀerent transcripts. Data are
expressed as fold decrease of mRNA expression in VPA or SAHA treated NK cells relative to untreated (control) NK cells. Histograms are
representative of results obtained with NK cells derived from three diﬀerent donors. Each experiment was run in triplicate; error bars indicate
±standard deviation (S.D.). (C) A 4 h NK cell cytotoxicity was assessed in a redirected killing assay against the FccR+ P815 target cell line either in
the presence or absence of mAbs to the indicated receptors. Columns represent means of triplicate of one representative experiment; error bars
indicate ±standard deviation (S.D.). (D) Cells were stimulated by cross-linking the indicated NK receptors with appropriate mAbs. After overnight
incubation at 37 C in IMDM+10% FCS alone, supernatants were collected and analyzed in an ELISA assay speciﬁc for invitro quantitative
determination of perforin release. Columns indicate perforin granule release (pg/ml). One representative of at least three separate experiments is
shown.
H. Ogbomo et al. / FEBS Letters 581 (2007) 1317–1322 1321Blanchard and Chipoy [19] reviewed several reports demon-
strating the inhibition of NFjB transcriptional activity after
treatment with HDACi. Here, mechanisms of NFjB transcrip-
tional inhibition by HDACi including inhibition of nuclear
translocation and DNA binding of NFjB were illustrated
[19]. Vitale et al. [14] demonstrated that the corticosteroid
methylprednisolone induces an inhibitory eﬀect on NK cell
function by downregulation of activating receptors involved
in natural cytotoxicity. They later showed that methylprednis-
olone not only results in downregulation of surface expression
or function of the activating receptors but also aﬀects phos-
phorylation of ERK1/2, thus inhibiting perforin release in
IL-2 treated NK cells [11]. It is interesting to mention that cor-
ticosteroids are known to eﬀectively inhibit NFjB activity [20].
This is consistent with ﬁndings which revealed that prevention
of NFjB activity by pharmacological treatments [18] or a
defective NFjB activation in patients with the genetic disorder
hypohidrotic ectodermal dysplasia [21] leads to a deﬁcient NK
cell cytotoxicity. In concordance, the present ﬁndings stronglyindicate that SAHA and VPA inhibit NK cell lytic activity by
suppressing NFjB activation.
VPA and other HDACi are being studied as potential treat-
ment for leukemia and myelodysplastic syndromes and early
reports suggest that they may have therapeutic eﬀects in some
forms of leukemia [1]. On the other hand, VPA therapy was
shown to be associated with the development of myelodysplas-
tic changes in the marrow and acute leukemia [22]. It has been
proposed that VPA therapy may lead to secondary leukemia
by increased DNA damage through chronic inhibition of
HDAC [22]. It has also been demonstrated that in acute mye-
loid leukemia (AML), NK cells express low levels of NCRs.
The insuﬃciency of NCR-ligand interactions has been hypoth-
esized as the underlying cause of the low susceptibility of leu-
kemic blasts to lysis by autologous NK cells [23]. It may be
speculated that VPA-induced downregulation of NCRs may
lead to deﬁcient immune control by NK cells and thus contrib-
ute to leukemogenesis associated with VPA therapy. It should
be noted that SAHA which is a more potent inhibitor of
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either 0.5 mM VPA or 0.5 lM SAHA or 1 lM BAY 11-7085 for 4
days. Primary NK cells treated only with 100 U/ml IL-2 were used as
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materials and methods. The relative luminescent values of IL-2 alone
were set to 100%, from which the percentage activation of other treated
NK cells were deduced. [m] indicate mutated consensus oligonucleo-
tide, [wt] indicate wild-type consensus oligonucleotide. Columns
represent means of triplicate of one representative experiment; error
bars indicate ±standard deviation (S.D.).
1322 H. Ogbomo et al. / FEBS Letters 581 (2007) 1317–1322HDAC than VPA [1] was also more potent inhibitor of NFjB
activation, NCR expression, and NK cell lytic activity against
leukemic cells. More studies are required especially with trea-
ted patients to further elucidate the multifaceted roles of
HDACi on NK cell activity.
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